Research programme: oral hBNP - Biocon
Alternative Names: BN-054; BNP 054; NBN 002; NBN 054; NBN 054 - BioconLatest Information Update: 16 Jul 2016
At a glance
- Originator Biocon
- Class Natriuretic peptides
- Mechanism of Action Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
- Discontinued Heart failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in India (PO)
- 26 Sep 2005 Data presented at the 9th Annual Scientific Meeting of the Heart Failure Society of America (HFSA-2005) have been added to the Heart failure pharmacodynamics section
- 30 Aug 2005 Nobex and Biocon have entered into an agreement to co-develop oral hBNP worldwide for for the treatment of heart failure and other portential cardiovascular disease indications